Investor Days 2026

25 – 26 Nov 2026 | Milan, Italy

Peptitech

SME

peptitech.com/Milan, Italy
8 profile visits

About

Social media

Areas of activity

Health

Biotech

Additional information

Establishment year

2019

Organization description

Peptitech is a preclinical-stage biopharmaceutical company founded in 2029 and headquartered in Milan, Italy. It operates as an independent legal entity with a proprietary patent portfolio protecting its compounds and mechanisms of action. The company maintains a lean organizational structure and collaborates with a network of scientific and industrial partners to support its development activities.

Business Project Description

Glutamate excitotoxicity drives neurodegeneration in glaucoma. Current therapies only lower eye pressure. Peptitech's GN-01GRi is a first-in-class eye-drop peptide selectively inhibiting presynaptic NMDA receptors, reducing toxic glutamate without blocking neurotransmission. Target: glaucoma, retinal diseases, Alzheimer's/Parkinson's. Model: out-licensing, co-development. Team: neuroscience, pharmacology, business. Funds will complete preclinical development, IND-enabling studies, regulatory prep.

Product/Technology Development Stage

Proof of concept

Team size

1-2

Team Background

BusinessScientific Research

IPR Status

IPR granted

Type of funding raised

Seed

Annual turnover (€)

100 - 500k

I participated in the Start Cup initiative of Lombardy Region

Yes

I received the Seal of Excellence for an EIC Accelerator project proposal

No

Representatives

Professor Pharmacology

Peptitech